SCHEMBL3483235

SCHEMBL3483235

O=C1NC(=O)/C(=C/c2cnn3ccc(-c4ccccc4F)nc23)N1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2B P67870 2/20 0.43
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
ALDH1A1 P00352 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MAPT P10636 2/20 0.40
PARP1 P09874 1/20 0.36
KDM4E B2RXH2 4/20 0.35
TGFBR1 P36897 3/20 0.35
HPGD P15428 3/20 0.34
GAA P10253 3/20 0.34
NPC1 O15118 2/20 0.34
TP53 P04637 1/20 0.34
RAB9A P51151 1/20 0.34
PKM P14618 1/20 0.34
POLB P06746 1/20 0.33
HSP90AA1 P07900 1/20 0.33
GRM2 Q14416 1/20 0.33
GSK3B P49841 1/20 0.33
CGAS Q8N884 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3482801 1.00 CSNK2B (0.43) CSNK2BMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL3482803 1.00 CSNK2B (0.43) CSNK2BMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL861524 0.81 IGF1R (0.52) MEN1KMT2AHPGDGAAGSK3B
SCHEMBL861523 0.81 IGF1R (0.52) MEN1KMT2AHPGDGAAGSK3B
SCHEMBL12979174 0.81 IGF1R (0.52) MEN1KMT2AHPGDGAAGSK3B
SCHEMBL3482965 0.80 MTOR (0.51) HPGDGSK3B
SCHEMBL3482962 0.80 MTOR (0.51) HPGDGSK3B
SCHEMBL3483024 0.80 MTOR (0.51) HPGDGSK3B
SCHEMBL860236 0.79 PARP1 (0.43) MEN1KMT2ASMN1; SMN2MAPTPARP1
SCHEMBL14679094 0.77 PARP1 (0.35) MEN1KMT2AALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367681-B2 Pyrazolopyrimidines and related heterocycles as kinase inhibitors CYLENE PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
US-8367681-B2 Pyrazolopyrimidines and related heterocycles as kinase inhibitors CYLENE PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
US-8367681-B2 Pyrazolopyrimidines and related heterocycles as kinase inhibitors CYLENE PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010135581-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM1, PIM2, PIM3 CSNK2B 71/4885MEN1 3936/4885KMT2A 1758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.